Hepion Pharmaceuticals votes reverse stock split of 1-for-20 to 1-for-50

• Hepion Pharmaceuticals majority stockholders executed written consent on Aug. 27, 2026, clearing a package of charter and equity-plan changes.
• Board gained authority to implement a reverse stock split within a 1-for-20 to 1-for-50 range, at its discretion.
• Charter amendment authorized a jump in common shares to 750,000,000 from 120,000,000, expanding capacity for future issuance.
• 2023 Omnibus Equity Incentive Plan share pool increased to 18,000,000 from 8,000,000; actions take effect at least 20 days post-mailing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hepion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-042187), on September 10, 2026, and is solely responsible for the information contained therein.